DEF: Genprex Sets 2026 Annual Meeting, Proposes Reverse Stock Split

Genprex, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to address key corporate matters including director elections, auditor ratification, executive compensation, and a proposed reverse stock split.

Summary

• Genprex, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 18, 2026.
• The meeting agenda includes the election of two Class III directors, ratification of WithumSmith+Brown, PC as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
• Stockholders will also vote on approving an amendment to the company's charter to effect a reverse stock split, with a ratio ranging from 1-for-5 to 1-for-50, to be implemented at the Board's discretion before December 31, 2027.
• Additionally, the meeting will cover the approval of an amended and restated 2018 Equity Incentive Plan and the potential adjournment of the meeting if necessary to solicit further proxies.
• Proxy materials will be mailed to stockholders of record as of April 24, 2026, with voting options available online, by telephone, and by mail.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the repeated need for reverse stock splits to maintain Nasdaq compliance, indicating ongoing stock price challenges, despite the proactive governance measures.

Positives

• The company is proactively seeking stockholder approval for key governance and strategic initiatives.
• The proposed reverse stock split aims to potentially improve the stock's marketability and maintain Nasdaq listing compliance.
• The virtual meeting format aims to increase stockholder participation and reduce costs.
• The company is seeking to amend and restate its 2018 Equity Incentive Plan to ensure continued ability to attract and retain talent.

Negatives

• The company has previously received listing deficiency notices for non-compliance with Nasdaq's Minimum Bid Price Requirement and has implemented two reverse stock splits in the past year (1:40 in Feb 2024, 1:50 in Oct 2025).
• The proposed reverse stock split carries risks, including the possibility that it may not increase the stock price or maintain Nasdaq compliance, and could potentially decrease liquidity.
• New Nasdaq rules may prevent the company from using future reverse stock splits for compliance if the stock price falls again within certain timeframes.
• The company's stock price has been volatile, trading as low as $1.15 in early 2026 and $1.71 in 2025.

Risks

• Failure to maintain compliance with Nasdaq's Minimum Bid Price Requirement could lead to delisting.
• The reverse stock split may not achieve its intended effects on stock price and marketability.
• The company's ability to use future reverse stock splits for compliance is restricted by new Nasdaq rules.
• The company's financial performance and market conditions could negatively impact its stock price regardless of the reverse stock split.

Future Outlook

The company is seeking stockholder approval for a reverse stock split to potentially improve its stock price and maintain Nasdaq listing compliance, and is also seeking approval for an amended equity incentive plan to support future talent acquisition and retention.

Management Comments

• "We believe that authorizing a reverse stock split now will provide the flexibility to effectuate a reverse stock split to respond to similar scenarios should they arise in the future."
• "Our Board believes that the Reverse Split is necessary to help maintain our listing on Nasdaq."
• "Our Compensation Committee and our Board of Directors believe that it is critical for us to continue to have the ability to offer competitive equity compensation awards to attract, retain and motivate the members of our management team and other key employees and service providers upon whom the Companys success depends."

Industry Context

StockSavvy.ai notes that Genprex's proposed reverse stock split is a common strategy for biotechnology and clinical-stage companies facing Nasdaq listing challenges due to low stock prices. The company's reliance on such measures highlights the inherent volatility and funding pressures within the sector.

Corporate Governance

Related Party Transactions

• Royalty payments of 1% of net sales are owed to Introgen Research Institute, Inc. (IRI), an entity owned by descendants of former CEO J. Rodney Varner, related to licensed technologies.
• A separation agreement was executed with Catherine M. Vaczy, former EVP, General Counsel, and Chief Strategy Officer, involving a payment of $350,000 and accelerated vesting of equity awards.

Stakeholder Impact

• Shareholders: The proposed reverse stock split could impact share price and liquidity. Approval of equity plans aims to align management and shareholder interests.
• Employees: The amended equity incentive plan provides continued opportunities for equity-based compensation.
• Management: Executive compensation is subject to an advisory vote, and management's equity awards are detailed.
• Board of Directors: Directors are up for election, and their compensation is detailed.

Next Steps

• Stockholders to vote on the proposed resolutions at the 2026 Annual Meeting on June 18, 2026.
• The Board of Directors will determine whether to implement the reverse stock split and at what ratio, if approved by stockholders, prior to December 31, 2027.
• The company will file final voting results in a Form 8-K within four business days of the Annual Meeting.

Key Dates

Recommendation

The company is taking necessary steps for corporate governance and potential stock price enhancement through a reverse stock split. However, the repeated need for such measures and the associated risks, coupled with the lack of specific financial performance updates in this filing, suggest a 'hold' recommendation. Investors should monitor clinical trial progress and future financial results closely.

Keywords

Genprex, DEF 14A, Proxy Statement, Annual Meeting, Reverse Stock Split, Equity Incentive Plan, Director Election, Auditor Ratification, Executive Compensation, Nasdaq Compliance